Metabolic and vascular effect of progestins in post-menopausal women - Implications for cardioprotection

被引：26

作者：

Rosano, GMC ^{[1
]}

Vitale, C ^{[1
]}

Silvestri, A ^{[1
]}

Fini, M ^{[1
]}

机构：

[1] Tosinvest Sanita, Dept Internal Med, Cardiovasc Res Unit, I-00168 Rome, Italy

来源：

MATURITAS | 2003年 / 46卷

关键词：

metabolic and vascular effect; progestins; cardioprotection; hormone replacement therapy; endothelial function; diabetes;

D O I：

10.1016/j.maturitas.2003.09.015

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Estrogen therapy causes changes in a variety of cardiovascular risk factors, including insulin resistance, lipoprotein profile, haemostasis, coronary atherosclerosis and vascular reactive, that suggest a potential cardioprotective effect in postmenopausal women. With respect to the role of adjunctive progestins, currently available data suggest that the cardiovascular effects may differ depending on the type, dosage and route of administration of the progestin. Androgenic progestins antagonise the favourable cardiovascular effect of estrogens, whilst non-androgenic progestins do not impair, or may even enhance, the beneficial effect of estrogens. Therefore, less androgenic progestins would appear to be the agent of choice for combined hormone therapy in postmenopausal women with cardiovascular risk factors. (C) 2003 Published by Elsevier Ireland Ltd.

引用

页码：S17 / S29

页数：13

共 56 条

[1] INHIBITION OF CORONARY-ARTERY ATHEROSCLEROSIS BY 17-BETA ESTRADIOL IN OVARIECTOMIZED MONKEYS - LACK OF AN EFFECT OF ADDED PROGESTERONE [J].

ADAMS, MR ;

KAPLAN, JR ;

MANUCK, SB ;

KORITNIK, DR ;

PARKS, JS ;

WOLFE, MS ;

CLARKSON, TB .

ARTERIOSCLEROSIS, 1990, 10 (06) :1051-1057

[2]

ADAMS MR, 1997, HORMONAL METABOLIC C, P39

[3]

*AM HEART ASS, 2001, 2002 HEART STROK STA

[4] Effect of oral postmenopausal hormone replacement on progression of atherosclerosis -: A randomized, controlled trial [J].

Angerer, P ;

Störk, S ;

Kothny, W ;

Schmitt, P ;

von Schacky, C .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (02) :262-268

[5] CORONARY HEART-DISEASE RISK-FACTORS IN WOMEN [J].

BREZINKA, V ;

PADMOS, I .

EUROPEAN HEART JOURNAL, 1994, 15 (11) :1571-1584

[6] CARDIOVASCULAR MORTALITY AND NONCONTRACEPTIVE USE OF ESTROGEN IN WOMEN - RESULTS FROM THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY [J].

BUSH, TL ;

BARRETTCONNOR, E ;

COWAN, LD ;

CRIQUI, MH ;

WALLACE, RB ;

SUCHINDRAN, CM ;

TYROLER, HA ;

RIFKIND, BM .

CIRCULATION, 1987, 75 (06) :1102-1109

[7]

CASTELLI WP, 1988, AM J OBSTET GYNECOL, V158, P1553, DOI 10.1016/0002-9378(88)90189-5

[8] Anti-ischemic effect of chronic oestrogen replacement therapy alone or in combination with medroxyprogesterone acetate in different replacement schemes [J].

Cerquetani, E ;

Leonardo, F ;

Pagnotta, P ;

Galetta, P ;

Onorati, D ;

Fini, M ;

Rosano, GMC .

MATURITAS, 2001, 39 (03) :245-251

[9]

CLARKSON TB, 2002, CARDIOVASCULAR HLTH, P231

[10] Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: Effects on serum lipoproteins and glucose tolerance during 24 month follow up [J].

Crook, D ;

Godsland, IF ;

Hull, J ;

Stevenson, JC .

BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (03) :298-304

← 1 2 3 4 5 6 →